Merck drug failure disappointing, but expectations were low, says Wells Fargo Wells Fargo views the failure of Merck's Tredaptive as disappointing, but said its expectations for the drug were low. The firm continues to expect significant positive near-term pipeline news flow and keeps an Outperform rating on Merck.
News For MRK From The Last 14 Days
Check below for free stories on MRK the last two weeks.
FDA approves Belsomra sleep drug The Food and Drug Administration approved Belsomra tablets for use as needed to treat difficulty in falling and staying asleep. Belsomra is an orexin receptor antagonist and is the first approved drug of this type. Belsomra will be dispensed with an FDA-approved patient Medication Guide that provides instructions for its use and important safety information. Belsomra is a controlled substance because it can be abused or lead to dependence. Belsomra is made by Merck, Sharpe & Dohme.